Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis
Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with...
Uložené v:
| Vydané v: | Cephalalgia Ročník 38; číslo 4; s. 754 |
|---|---|
| Hlavní autori: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
01.04.2018
|
| Predmet: | |
| ISSN: | 1468-2982, 1468-2982 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and quality of evidence has not been formally evaluated. Objectives To determine the effectiveness of progestin-only contraceptives for migraine treatment by systematic review and meta-analysis. Data sources and selection MEDLINE, EMBASE and Cochrane Libraries were searched (1980 to September 2016) for studies on progestin-only treatments for migraine. Studies in English on >4 non-menopausal women aged 18-50 with migraine diagnosed by formal criteria were included. Data extraction and analysis Data were quality-assessed using the GRADE system. A random effects model was used for pooled analyses. Results Pooled analyses of four studies demonstrated that desogestrel 75 mcg/day, POP significantly but modestly reduced the number of migraine attacks and migraine days. Reduced intensity and duration, reduced analgesic and triptan use were observed, along with improved headache-related quality of life. GRADE analysis indicated evidence was low to very low for each outcome measure. Adverse effects resulted in treatment cessation for <10% of participants. Two studies compared desogestrel POP to a combined oral contraceptive, demonstrating similar migraine outcomes for both treatments. Conclusions The desogestrel POP shows promise in improving migraine in women. Current evidence is observational and based on small samples of women using only one oral progestin-only formulation. Further randomized trials on additional progestin-only contraceptives are required to confirm their role in migraine management. |
|---|---|
| AbstractList | Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and quality of evidence has not been formally evaluated. Objectives To determine the effectiveness of progestin-only contraceptives for migraine treatment by systematic review and meta-analysis. Data sources and selection MEDLINE, EMBASE and Cochrane Libraries were searched (1980 to September 2016) for studies on progestin-only treatments for migraine. Studies in English on >4 non-menopausal women aged 18-50 with migraine diagnosed by formal criteria were included. Data extraction and analysis Data were quality-assessed using the GRADE system. A random effects model was used for pooled analyses. Results Pooled analyses of four studies demonstrated that desogestrel 75 mcg/day, POP significantly but modestly reduced the number of migraine attacks and migraine days. Reduced intensity and duration, reduced analgesic and triptan use were observed, along with improved headache-related quality of life. GRADE analysis indicated evidence was low to very low for each outcome measure. Adverse effects resulted in treatment cessation for <10% of participants. Two studies compared desogestrel POP to a combined oral contraceptive, demonstrating similar migraine outcomes for both treatments. Conclusions The desogestrel POP shows promise in improving migraine in women. Current evidence is observational and based on small samples of women using only one oral progestin-only formulation. Further randomized trials on additional progestin-only contraceptives are required to confirm their role in migraine management. Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and quality of evidence has not been formally evaluated. Objectives To determine the effectiveness of progestin-only contraceptives for migraine treatment by systematic review and meta-analysis. Data sources and selection MEDLINE, EMBASE and Cochrane Libraries were searched (1980 to September 2016) for studies on progestin-only treatments for migraine. Studies in English on >4 non-menopausal women aged 18-50 with migraine diagnosed by formal criteria were included. Data extraction and analysis Data were quality-assessed using the GRADE system. A random effects model was used for pooled analyses. Results Pooled analyses of four studies demonstrated that desogestrel 75 mcg/day, POP significantly but modestly reduced the number of migraine attacks and migraine days. Reduced intensity and duration, reduced analgesic and triptan use were observed, along with improved headache-related quality of life. GRADE analysis indicated evidence was low to very low for each outcome measure. Adverse effects resulted in treatment cessation for <10% of participants. Two studies compared desogestrel POP to a combined oral contraceptive, demonstrating similar migraine outcomes for both treatments. Conclusions The desogestrel POP shows promise in improving migraine in women. Current evidence is observational and based on small samples of women using only one oral progestin-only formulation. Further randomized trials on additional progestin-only contraceptives are required to confirm their role in migraine management.Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and quality of evidence has not been formally evaluated. Objectives To determine the effectiveness of progestin-only contraceptives for migraine treatment by systematic review and meta-analysis. Data sources and selection MEDLINE, EMBASE and Cochrane Libraries were searched (1980 to September 2016) for studies on progestin-only treatments for migraine. Studies in English on >4 non-menopausal women aged 18-50 with migraine diagnosed by formal criteria were included. Data extraction and analysis Data were quality-assessed using the GRADE system. A random effects model was used for pooled analyses. Results Pooled analyses of four studies demonstrated that desogestrel 75 mcg/day, POP significantly but modestly reduced the number of migraine attacks and migraine days. Reduced intensity and duration, reduced analgesic and triptan use were observed, along with improved headache-related quality of life. GRADE analysis indicated evidence was low to very low for each outcome measure. Adverse effects resulted in treatment cessation for <10% of participants. Two studies compared desogestrel POP to a combined oral contraceptive, demonstrating similar migraine outcomes for both treatments. Conclusions The desogestrel POP shows promise in improving migraine in women. Current evidence is observational and based on small samples of women using only one oral progestin-only formulation. Further randomized trials on additional progestin-only contraceptives are required to confirm their role in migraine management. |
| Author | Warhurst, Samantha Merki-Feld, Gabriele S Bateson, Deborah McGeechan, Kevin Brew, Bruce J Garrick, Raymond Rofe, Christopher J Tomlinson, Susan E |
| Author_xml | – sequence: 1 givenname: Samantha surname: Warhurst fullname: Warhurst, Samantha organization: 1 Timaru Hospital, Timaru, Canterbury, New Zealand – sequence: 2 givenname: Christopher J surname: Rofe fullname: Rofe, Christopher J organization: 2 St Vincent's Hospital, Darlinghurst, Sydney, Australia – sequence: 3 givenname: Bruce J surname: Brew fullname: Brew, Bruce J organization: 3 Faculty of Medicine, University of New South Wales, Sydney, Australia – sequence: 4 givenname: Deborah surname: Bateson fullname: Bateson, Deborah organization: 5 Family Planning NSW, Ashfield, New South Wales, Australia – sequence: 5 givenname: Kevin surname: McGeechan fullname: McGeechan, Kevin organization: 5 Family Planning NSW, Ashfield, New South Wales, Australia – sequence: 6 givenname: Gabriele S surname: Merki-Feld fullname: Merki-Feld, Gabriele S organization: 6 Clinic for Reproductive Endocrinology, University Hospital Zurich, Switzerland – sequence: 7 givenname: Raymond surname: Garrick fullname: Garrick, Raymond organization: 2 St Vincent's Hospital, Darlinghurst, Sydney, Australia – sequence: 8 givenname: Susan E surname: Tomlinson fullname: Tomlinson, Susan E organization: 4 Faculty of Medicine, University of Sydney, New South Wales, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28554244$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLAzEYRYNUbK3uXUmWbkbznhl3pdQHFNzoekgzX2pkktRJ2jL_3gEruLpncblw7iWahBgAoRtK7iktywfCOaeEiZEpUVydoRkVqipYXbHJP56iy5S-CCFSEXWBpqySUjAhZiiurAWT3QECpISjxfkT8K6PW0jZhSKGbsA713XYxh57t-21C4BzDzp7CBm7gI9xpEe8wGlIGbzOzuAeDg6OWIcWe8i60EF3Q3LpCp1b3SW4PuUcfTyt3pcvxfrt-XW5WBeGl3UuOLWlqQxoKm2liSh52VKQplW83hjLqGCyVhIsbEzFbE0rwbTUkqtWKDa6zdHd7-6o8r0fXRrvkoGu0wHiPjW0JrwWvJRkrN6eqvuNh7bZ9c7rfmj-TmI_2wJsHA |
| CitedBy_id | crossref_primary_10_1080_09513590_2023_2239936 crossref_primary_10_1038_s41582_021_00544_2 crossref_primary_10_3389_fneur_2025_1648017 crossref_primary_10_1186_s10194_025_01998_1 crossref_primary_10_1016_j_ncl_2019_07_002 crossref_primary_10_1097_WCO_0000000000000926 crossref_primary_10_34175_jno202201003 crossref_primary_10_3390_jcm13113027 crossref_primary_10_51847_pwe8n12qJ3 crossref_primary_10_1007_s11910_018_0845_3 crossref_primary_10_1097_01_NPR_0000669156_23456_a3 crossref_primary_10_3390_jpm14020184 crossref_primary_10_1080_14737175_2023_2296610 crossref_primary_10_1111_head_13665 crossref_primary_10_1007_s00415_020_09726_2 crossref_primary_10_1186_s10194_018_0922_7 crossref_primary_10_1097_01_PGO_0000549717_36699_d6 crossref_primary_10_1186_s10194_024_01804_4 crossref_primary_10_1186_s10194_018_0896_5 crossref_primary_10_1016_j_pop_2020_02_004 crossref_primary_10_1016_j_maturitas_2020_07_005 crossref_primary_10_1080_13625187_2019_1605504 crossref_primary_10_1016_j_ejogrb_2019_07_021 crossref_primary_10_1080_13697137_2018_1439914 crossref_primary_10_3390_biomedicines11061613 crossref_primary_10_1007_s13669_023_00349_8 crossref_primary_10_1016_j_expneurol_2025_115139 crossref_primary_10_1016_j_clineuro_2017_12_026 crossref_primary_10_1007_s40120_025_00720_2 crossref_primary_10_1016_j_jogn_2018_04_137 crossref_primary_10_1080_14737175_2023_2198705 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1177/0333102417710636 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-2982 |
| ExternalDocumentID | 28554244 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- -TM .2F .2G .3N .GJ .Y3 01A 0R~ 1OC 29B 31S 31T 31Y 31~ 36B 4.4 53G 54M 5GY 5RE 5VS 6PF 8-1 AABMB AABOD AACKU AADUE AAGGD AAHHS AAJIQ AAJOX AAJPV AANSI AAPEO AAQDB AAQXH AARDL AARIX AASGM AAWTL AAXOT AAYTG AAZBJ ABAWC ABAWP ABCCA ABCQN ABDBF ABDWY ABEIX ABFWQ ABHKI ABIVO ABJIS ABJNI ABKRH ABNCE ABPGX ABQKF ABQXT ABRHV ABVFX ABVVC ABYTW ACARO ACCFJ ACDSZ ACDXX ACFMA ACFYK ACGBL ACGFS ACLHI ACNXM ACOFE ACROE ACRPL ACUHS ACXQS ADBBV ADEIA ADMPF ADNBR ADNMO ADOGD ADTBJ ADUKL ADYCS ADZOD ADZYD ADZZY AECVZ AEEZP AENEX AEQDE AEQLS AERKM AEUHG AEWDL AEXFG AEXNY AFBPY AFCOW AFEBI AFEET AFKBI AFKRG AFRWT AFUIA AFVCE AFWMB AFZJQ AGNHF AHEFC AIGRN AIWBW AJABX AJAOE AJBDE AJEFB AJMMQ AJSCY AJUZI AJXGE ALMA_UNASSIGNED_HOLDINGS ARTOV ASPBG AUTPY AVWKF AYAKG AZFZN B8M B8O B93 BDDNI BFHJK BKSCU BSEHC BYIEH CAG CBRKF CDWPY CFDXU CGR CO8 COF CORYS CQQTX CS3 CUTAK CUY CVF DC- DC. DC0 DC6 DCZOG DD- DD0 DE- DOPDO DU5 D~Y EAD EAP EAS EBC EBD EBS EBX ECM ECV EIF EJD EMB EMK EMOBN ENC EPT ESX F5P FEDTE FZ0 GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HVGLF HZI HZ~ IHE J8X K.F K.J K97 LH4 LW6 M4V N9A NPM O9- OIG OVD P.B P2P Q1R Q7K Q7R Q7X Q82 Q~Q ROL S01 SAUOL SCDPB SCNPE SFC SV3 TEORI TUS W99 WYUIH YFH ZGI ZONMY ZPPRI ZRKOI ZSSAH 7X8 ACHEB ADEBD SASJQ |
| ID | FETCH-LOGICAL-c379t-31f7c8cea15f8a04737d1e5cd639bcf21425965efebc82f91842a5a536d462542 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 34 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000429772700016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1468-2982 |
| IngestDate | Fri Jul 11 13:41:31 EDT 2025 Thu Apr 03 07:26:13 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Desogestrel migraine progestogen contraception headache menstrual migraine progesterone |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c379t-31f7c8cea15f8a04737d1e5cd639bcf21425965efebc82f91842a5a536d462542 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 28554244 |
| PQID | 1903943750 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1903943750 pubmed_primary_28554244 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-04-00 20180401 |
| PublicationDateYYYYMMDD | 2018-04-01 |
| PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-00 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Cephalalgia |
| PublicationTitleAlternate | Cephalalgia |
| PublicationYear | 2018 |
| SSID | ssj0005606 |
| Score | 2.4065838 |
| SecondaryResourceType | review_article |
| Snippet | Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 754 |
| SubjectTerms | Adolescent Adult Contraceptives, Oral, Synthetic - therapeutic use Desogestrel - therapeutic use Female Humans Migraine Disorders - drug therapy Progestins - therapeutic use Young Adult |
| Title | Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28554244 https://www.proquest.com/docview/1903943750 |
| Volume | 38 |
| WOSCitedRecordID | wos000429772700016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbyGtpvNJvEiRSxeWnpQ6G3JZhNZaLPVVsF_72Q37Z4EwcveAstkMt83mck3CN31pO7mJvFpCWckZlYRLytOepkB-ipgy1VWDZvgo5GYTOQ4XLgtQlvlKiZWgTovtb8j7wBwURlTALiH-TvxU6N8dTWM0NhELQpUxh9MPmnUwgHN16-LIimipkzZ6VIKxAbgiwPEJjT5nWBWQDPY_-8vHqC9QDFxv_aJQ7Rh3BHaGYYi-jEqa8XiEOZwaTGQQOwbtbzihiOlm37jeTGdYiC0eFa8-SkSBq9b0nHhcCXccI_7uFGCxvUrGKxcjmdmqYgKeicn6HXw9PL4TMLcBaIpl0sIy5ZroY3qMStUN-aU5z3DdA5sJtPWi7QxmTBjTaZFZCUkiZFiitEkjyGdiqNTtOVKZ84RtpAeRhbsy6WF1DETGYftNzwGlsnBDdrodmXKFPzaFyuUM-XnIm2M2UZn9X6k81qAI418bx3wkos_rL5Eu8BxRN1sc4VaFk61uUbb-mtZLD5uKoeB72g8_AGzB8n3 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+the+progestin-only+pill+for+migraine+treatment+in+women%3A+A+systematic+review+and+meta-analysis&rft.jtitle=Cephalalgia&rft.au=Warhurst%2C+Samantha&rft.au=Rofe%2C+Christopher+J&rft.au=Brew%2C+Bruce+J&rft.au=Bateson%2C+Deborah&rft.date=2018-04-01&rft.eissn=1468-2982&rft.volume=38&rft.issue=4&rft.spage=754&rft_id=info:doi/10.1177%2F0333102417710636&rft_id=info%3Apmid%2F28554244&rft_id=info%3Apmid%2F28554244&rft.externalDocID=28554244 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1468-2982&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1468-2982&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1468-2982&client=summon |